Trials / Recruiting
RecruitingNCT07310095
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Xian-Janssen Pharmaceutical Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab (GUS) | Guselkumab will be administered intravenously or by subcutaneous injection. |
Timeline
- Start date
- 2025-12-30
- Primary completion
- 2027-09-15
- Completion
- 2027-11-15
- First posted
- 2025-12-30
- Last updated
- 2026-04-13
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07310095. Inclusion in this directory is not an endorsement.